We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Interfering Peptides Targeting Protein-Protein Interactions

Video   Jun 19, 2015

 


About the Speaker
Katja M. Arndt is Professor of Molecular Biotechnology at the University of Potsdam. She received her Ph.D. in Biochemistry under the supervision of Professor Andreas Plückthun, University of Zurich, Switzerland, and Professor Tom Alber, University of California, Berkeley. With the acceptance to the Emmy-Noether Excellence program of the German Research Foundation (DFG) in 2003, Katja M. Arndt became head of the group 'Protein Engineering in Biosystems' in the Department of Biology, University of Freiburg, Germany. In 2008, she became a principle investigator in the excellence cluster 'BIOSS' (biological signaling studies) and was appointed as Junior Fellow in the School of Life Sciences (LIFENET) of the Freiburg Institute for Advanced Studies (FRIAS). She was appointed to the faculty of the University of Potsdam as a Full Professor of Molecular Biotechnology in 2010. Her academic achievements have been recognized by many awards and scholarships. Her work focuses on evolutionary protein engineering utilizing different selection systems. She pioneered the field of interfering peptides for disrupting protein-protein interactions. Recently she was involved in tailoring a viral system for cytoplasmic gene delivery to tumor cells.Abstract
Protein-protein interaction surfaces are attractive yet challenging targets for disease intervention. We present strategies to combine rational design with in-vivo and in-vitro selection systems and implementing competitive and negative design aspects to simultaneously select for affinity and specificity. Using such a semi-rational evolutionary approach, we generated interfering peptides (iPEP) specifically directed against the coiled-coil interaction motif as found in transcription factors such as Jun, Fos, AF10 and MITF. Modifications such as photo-switchable iPEPs for external control of inhibitor activity and D-peptides for protease resistance will be discussed as well. Specific targeting of tumor cells and efficient cellular delivery has been implemented by a modular virus system based on the adeno-associated virus. 

 
 
 
 

Recommended Videos

How To Build a Cancer Killing Molecule

Video

Can molecules help lead the war against cancer?

In this talk, Dr. Patrick Gunning describes the seemingly insurmountable challenges that a medicinal chemist and drug discovery team face in their efforts to identify new drug molecules.

WATCH NOW

ADDomer – A New Kind of Vaccine for Untreatable Infection

Video

Scientists from the University of Bristol, CNRS and Imophoron Ltd worked with the computer technology giant Oracle to develop a new kind of vaccine that needs no refrigeration. They used synthetic biology, cryo-electron microscopy and high-performance cloud computing to produce a candidate vaccine against the mosquito-borne chikungunya virus. Their findings could revolutionise the way vaccines are designed, developed and stored.

WATCH NOW

Protein Superglue! What This Means for Drug Discovery?

Video

Can we make drugs that not only break/inhibit interactions between a protein and a ligand, but rather bestow new functionality? Nicolas Thomä explores molecular glue drugs, and their potential to make much needed medicines that were previously out of reach.

WATCH NOW

 

Like what you just watched? You can find similar content on the communities below.

Drug Discovery Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE